



Press Release Oct. 6, 2021

Genovis AB (publ.) hires new CFO

Genovis has hired Magnus Långberg as the new CFO of the Group; he will begin in January 2022.

Magnus Långberg has over 20 years of experience from a variety of positions within finance and management at international life science companies. He will be joining Genovis from his most recent position at Hemocue AB. Before that he worked at companies such as QPharma and BD Medical.

“I’m pleased to be able to welcome Magnus Långberg as the new CFO of Genovis. Magnus will have an important role in Genovis’ continued development and I look forward to working with him,” says Fredrik Olsson, CEO of Genovis.

For more information, please contact:

Fredrik Olsson, CEO, Genovis AB,

Telephone: +46 (0)70 276 46 56

Email: fredrik.olsson@genovis.com

Genovis’ business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.